KYTX Kyverna Therapeutics, Inc.

NASDAQ
$4.70

Kyverna Therapeutics, Inc. (KYTX) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.74 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.2% since its last earnings release on November 12, 2026.

Kyverna Therapeutics Reported In-line with Estimates
Thursday, November 12, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.74)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.91

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Kyverna Therapeutics, Inc.

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.